Pro-inflammatory gene expression and neurotoxic effects of activated microglia are attenuated by absence of CCAAT/enhancer binding protein β
© Straccia et al; licensee BioMed Central Ltd. 2011
Received: 10 August 2011
Accepted: 10 November 2011
Published: 10 November 2011
Microglia and astrocytes respond to homeostatic disturbances with profound changes of gene expression. This response, known as glial activation or neuroinflammation, can be detrimental to the surrounding tissue. The transcription factor CCAAT/enhancer binding protein β (C/EBPβ) is an important regulator of gene expression in inflammation but little is known about its involvement in glial activation. To explore the functional role of C/EBPβ in glial activation we have analyzed pro-inflammatory gene expression and neurotoxicity in murine wild type and C/EBPβ-null glial cultures.
Due to fertility and mortality problems associated with the C/EBPβ-null genotype we developed a protocol to prepare mixed glial cultures from cerebral cortex of a single mouse embryo with high yield. Wild-type and C/EBPβ-null glial cultures were compared in terms of total cell density by Hoechst-33258 staining; microglial content by CD11b immunocytochemistry; astroglial content by GFAP western blot; gene expression by quantitative real-time PCR, western blot, immunocytochemistry and Griess reaction; and microglial neurotoxicity by estimating MAP2 content in neuronal/microglial cocultures. C/EBPβ DNA binding activity was evaluated by electrophoretic mobility shift assay and quantitative chromatin immunoprecipitation.
C/EBPβ mRNA and protein levels, as well as DNA binding, were increased in glial cultures by treatment with lipopolysaccharide (LPS) or LPS + interferon γ (IFNγ). Quantitative chromatin immunoprecipitation showed binding of C/EBPβ to pro-inflammatory gene promoters in glial activation in a stimulus- and gene-dependent manner. In agreement with these results, LPS and LPS+IFNγ induced different transcriptional patterns between pro-inflammatory cytokines and NO synthase-2 genes. Furthermore, the expressions of IL-1β and NO synthase-2, and consequent NO production, were reduced in the absence of C/EBPβ. In addition, neurotoxicity elicited by LPS+IFNγ-treated microglia co-cultured with neurons was completely abolished by the absence of C/EBPβ in microglia.
These findings show involvement of C/EBPβ in the regulation of pro-inflammatory gene expression in glial activation, and demonstrate for the first time a key role for C/EBPβ in the induction of neurotoxic effects by activated microglia.
Glial activation is an inflammatory process that occurs in astrocytes and microglia to re-establish homeostasis of the CNS after a disequilibrium of normal physiology. Microglia are tissue-associated macrophages that keep the CNS under dynamic surveillance. Most insults to the CNS switch microglia into an M1-like phenotype, characterized by production of pro-inflammatory cytokines, reactive oxygen/nitrogen species and prostanoids. Scavenger receptors and chemokines are also upregulated and phagocytic activity increases. An M2-like phenotype usually follows, characterized by production of interleukin-4 (IL-4), IL-10, transforming growth factor-β and neurotrophic factor . Glial activation requires massive and fine-tuned re-arrangements in gene transcription. The transcription factors behind this process include nuclear factor-kB, which seems to mediate early-immediate cytokine and chemokine gene responses in glial activation [2, 3], and other transcription factors with a pro-inflammatory profile such as AP-1 , STATs , HIF-1 [5–7], Egr-1 , IRF1 . On the other hand, transcription factors such as PPARs  or Nrf2 [11, 12] play an anti-inflammatory role in glial activation.
CCAAT/enhancer binding protein β (C/EBPβ) is a candidate to regulate pro-inflammatory gene expression in glial activation. C/EBPβ is one of seven members of the C/EBP subfamily of bZIP transcription factors. At least three N-terminally truncated isoforms are known: 38-kDa Full, 35-kDa LAP and 21-kDa LIP [13, 14]. C/EBPβ transcriptional functions in cell energy metabolism, cell proliferation and differentiation are well-characterized [15, 16]. C/EBPβ also plays a role in inflammation . Promoters of many pro-inflammatory genes contain putative C/EBPβ consensus sequences [18–20] and C/EBPβ levels are upregulated in response to pro-inflammatory stimuli in macrophages  and glial cells [22–25]. Interestingly, C/EBPβ deficiency provides neuroprotection following ischemic  or excitotoxic injuries .
Several lines of evidence suggest that glial activation is involved in the pathogenesis of many neurological disorders. The present study stems from this hypothesis and from the hypothesis that there is a regulatory role for C/EBPβ in pro-inflammatory gene expression in neuroinflammation. To define the transcriptional role of C/EBPβ in glial activation we have here studied pro-inflammatory gene profiles and neurotoxicity in glial cultures from C/EBPβ-null mice. Our results show for the first time that absence of C/EBPβ attenuates pro-inflammatory gene expression and abrogates neuronal loss induced by activated microglia.
A colony of C/EBPβ+/-  mice on a C57BL/6-129S6/SvEv background was maintained. Animals from this colony showed no serological evidence of pathological infection. The animals were group-housed (5-6) in solid floor cages and received a commercial pelleted diet and water ad libitum. Experiments were carried out in accordance with the Guidelines of the European Union Council (86/609/EU) and following the Spanish regulations (BOE 67/8509-12, 1988) for the use of laboratory animals, and were approved by the Ethics and Scientific Committees from the Hospital Clínic de Barcelona.
DNA extraction and genotyping
Genomic DNA was isolated from 2 mg liver samples using Extract-N-AmpTissue PCR Kit (Sigma-Aldrich, XNAT2) following kit instructions. PCR amplification was performed in 20 μl total volume, using 1 μl of tissue extract, 0.8 μM C/EBPβ-1s forward primer (AAgACggTggACAAgCTgAg), 0.4 μM C/EBPβ-NeoAs (CATCAgAgCAgCCgATTgTC) and 0.4 μM C/EBPβ-4As (ggCAgCTgCTTgAACAAg TTC) reverse primers. Samples were run for 35 cycles (94°C for 30 s, 59°C for 30 s, 72°C for 90 s).
Cortical mixed glial culture from a single embryo
C/EBPβ+/- mice were crossed and pregnant females were sacrificed on the 19th day of gestation by cervical dislocation. Embryos (E19) were surgically extracted from the peritoneal cavity. Their livers were dissected and used to genotype the animal, whereas their brains were dissected and processed as previously described  with minor modifications. Cultures reached confluence after 16 ± 3 days in vitro (DIV) and were then subcultured.
Mouse mixed glial subculture
Each flask was washed in serum-free medium and was digested with 0.25% trypsin-EDTA solution for 5 min at 37°C. Trypsinization was stopped by adding an equal volume of culture medium with FBS 10%. Cells were pelleted (7 min, 180 g), resuspended in 1 mL culture medium, and brought to a single cell suspension by repeated pipetting. Cells were seeded at 166000 cells/mL. These were therefore secondary cultures and they were used at 12 ± 3 DIV. Astrocytes were the most abundant cell type and microglial cells were approximately 20%.
Microglial cultures were prepared by mild trypsinization from mouse mixed glial culture as previously described .
Primary cortical neuronal culture
Cortical neuronal cultures were prepared from C57BL/6 mice at embryonic day 16 as described . Neuronal cultures were used at 5 DIV.
Primary neuronal-microglial co-cultures
Microglial cultures were obtained as described . After astrocyte removal, microglial cells were incubated with 0.25% trypsin for 10 min at 37°C. Trypsinization was stopped by adding the same volume of culture medium with 10% FBS. Cells were gently scraped and centrifuged for 5 min at 200 g. Pellets were resuspended in neuronal culture medium and aliquots of the cell suspension (10 μL/well) were seeded on top of 5 DIV primary neuronal cultures at a final density of 4 × 105 cells/mL (1.3 × 105 cells/cm2).
In vitro treatments
Mixed glial cultures: The culture medium was replaced 24 h prior to treatment. Mixed glial cultures were treated with 100 ng/mL lipopolysaccharide (LPS, Sigma-Aldrich, L-2654, E. coli serotype 026:B6) and 0.1 ng/mL recombinant mouse interferon-γ (IFNγ, Sigma-Aldrich, I4777) prepared from x10 solutions.
Neuronal-primary microglia co-cultures: 100 ng/mL LPS and 30 ng/mL IFNγ were added to the culture medium one day after seeding primary microglial cells on top of neuronal cultures.
NO production was assessed by the Griess reaction. Briefly, 50 μL aliquots of culture supernatants were collected 48 h after LPS+IFNγ treatment, and incubated with equal volumes of Griess reagent (1% sulphanilamide, 0.1% N-(1-naphthyl)ethylendiamine dihydrochloride, and 5% phosphoric acid) for 10 min at room temperature (RT). Optical density at 540 nm was determined using a microplate reader (Multiskan spectrum, Thermo Electron Corporation). Nitrite concentration was determined from a sodium nitrite standard curve.
Electrophoretic mobility shift assay
Nuclear extracts were prepared as described  with a few modifications. Nuclear protein was extracted from mixed glial cultures after 2 h LPS or LPS+IFNγ treatment. Cells from two wells of 6-well plate were scrapped into cold 0.01 M phosphate-buffered saline (PBS, pH 7.4) and centrifuged for 4 min, 4500 g at +4°C. The resulting pellet was resuspended in 400 μL of buffer A: 10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM phenylmethylsulphonyl fluoride (PMSF) and 1 mM dithiothreitol (DTT) and cells were swollen on ice for 15 min. After addition of 25 μL of 10% Igepal CA-630 (Sigma-Aldrich, I8896), cells were vigorously vortexed for 10 s and incubated for 10 min on ice, then a 10-min centrifugation at 13200 g was performed and the pellets were resuspended in 50 μL of buffer C consisting of 20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF and 1 mM DTT. Solutions A, B, C and PBS were supplemented with protease inhibitor cocktail Complete® (Roche, 1836145). After 2 h of shaking at 4°C, nuclei were pelleted by a 5 min spin at 2000 g. The supernatant containing nuclear proteins was collected and protein amount was determined by the Lowry assay (Total Protein kit micro-Lowry, Sigma-Aldrich, TP0300). Oligonucleotides containing C/EBP consensus sequences (Santa Cruz Biotechnology, sc-2525) were labelled at their 3'-end using [α-33P]dATP (3000 Ci/mmol; Dupont-NEN, NEG-612H) and terminal deoxynucleotidyltransferase (TdT; Oncogene Research Products, PF060), and purified using illustra MicroSpin G-50 Columns (GE, 27-5330-01). Five micrograms of nuclear proteins were incubated for 30 min at RT with the labelled oligonucleotides (25000 cpm/reaction assay) in binding buffer (20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 50 mM Tris-HCl, 250 mM NaCl and 0.2 mg/mL Poly(dI:dC)). After the addition of Hi-Density TBE buffer to samples (15% Ficoll type 400, 1x TBE, 0.1% Bromophenol Blue, 0.1% Xylene Cyanol), proteins were separated by electrophoresis on a 6% DNA retardation gel (Invitrogen, EC6365BOX) at 4°C, 90 min at 100 V in 0.5x TBE buffer. In supershift assay, 0.5 μg of rabbit anti-mouse C/EBPβ (Santa Cruz Biotechnology, sc-150) or IgG (Santa Cruz Biotechnology, No.sc-2027) were added 10 min before oligonucleotide incubation.
Total protein extraction
Protein levels were determined in primary mixed glial cells 16 h after treatments. For isolation of total proteins, two wells from 6-well plates were used per condition. After a cold PBS wash, cells were scrapped and recovered in 100 μL per well of RIPA buffer (1% Igepal CA-630, 5 mg/mL sodium deoxycholate, 1 mg/mL sodium dodecyl phosphate (SDS) and protease inhibitor cocktail Complete® in PBS). The content of the wells was pooled, sonicated, centrifuged for 5 min at 10400 g and stored at -20°C. Protein amount was determined by the Lowry assay.
Fifty micrograms of denatured (2.5 mM DTT, 100°C for 5 min) total protein extracts were subjected to 10% SDS-PAGE and transferred to a PVDF membrane (Millipore, IPVH00010) for 90 min at 1 mA/cm2. After washing in Tris-buffered saline (TBS: 20 mM Tris, 0.15 M NaCl, pH 7.5) for 5 min, dipping in methanol for 10 s and air drying, the membranes were incubated with primary antibodies overnight at 4°C: polyclonal rabbit anti-C/EBPβ (1:500, Santa Cruz Biotechnology, sc-150), monoclonal mouse anti-NO synthase-2 (NOS2; 1:200, BD Transduction Laboratories, 610431), monoclonal mouse anti-βactin (1:100000, Sigma-Aldrich, A1978) and polyclonal rabbit anti-GFAP (1:10000, DakoCytomation, Z0334) diluted in immunoblot buffer (TBS containing 0.05% Tween-20 and 5% no-fat dry milk). Then, the membranes were washed twice in 0.05% Tween-20 in TBS for 15 s and incubated in horseradish peroxidase (HRP)-labelled secondary antibodies for 1 h at RT: donkey anti-rabbit (1:5000, GE, NA934) or goat anti-mouse (1:5000, Santa Cruz Biotechnology, sc-2055). After extensive washes in 0.05% Tween-20 in TBS, they were incubated in ECL-Plus (GE, RPN2132) for 5 min. Membranes were then exposed to the camera of a VersaDoc System (Bio-Rad), and pixel intensities of the immunoreactive bands were quantified using the percentage adjusted volume feature of Quantity One 5.4.1 software (Bio-Rad). Data are expressed as the ratio between the intensity of the protein of interest band and the loading control protein band (β-actin).
Quantitative real time PCR (qPCR)
Primers used in quantitative real time PCR.
Primer forward (5→3')
Primer reverse (5→3')
Quantitative chromatin immunoprecipitation (qChIP)
C/EBPβ binding sites and primers used in quantitative ChIP assay.
C/EBPβ binding site sequence (5→3') Consensus: ATTGCGCAAT
Genomic localization respect to ATG
Primer forward (5→3')
Primer reverse (5→3')
Cultured cells were fixed with 4% paraformaldehyde in PBS for 20 min at RT. For immunocytochemistry using fluorescence labelling, cells were permeated with chilled methanol for 7 min, then washed with PBS. Cells were incubated overnight at 4°C with 7% normal goat serum (Vector, S-1000) in PBS containing 1% Thimerosal (Sigma-Aldrich, T5125) and primary antibodies: polyclonal rabbit anti-C/EBPβ (1:500, Santa Cruz Biotechnology, sc-150), monoclonal mouse anti-NOS2 (1:200, BD Transduction Laboratories, 610431), polyclonal rabbit anti-GFAP (1:1000, DakoCytomation, Z0334) and monoclonal rat anti-CD11b (1:300, Serotec, MCA711G, clone 5C6). After rinsing in PBS, cells were incubated for 1 h at RT with secondary antibodies: goat anti-mouse Alexa 546 (1:1000, Molecular Probes, A-11018), goat anti-rabbit Alexa 546 (1:1000, Molecular Probes A-11010), Alexa 488 (1:1000, Molecular Probes, A-11070) or goat anti-rat Alexa 488 (1:500, Molecular Probes, A-11006). After secondary antibody incubation, cells were stained with Hoechst 33258 for 7 min. For immunocytochemistry using peroxidase labelling, cells were permeated and endogenous peroxidase activity was blocked by incubation with 0.3% H2O2 in methanol for 10 min. Non-specific staining was blocked by incubating the cells with 10% normal goat serum in PBS containing 1% BSA for 20 min at RT. The cells were then incubated with monoclonal mouse anti-MAP2 primary antibody (1:2000, Sigma-Aldrich, M1406) overnight at 4°C. In MAP2 staining, biotinylated horse anti-mouse secondary antibody (1:200, Vector, BA-2000) for 1 h at RT. Following incubation with ExtrAvidin®-Peroxidase (1:500, Sigma-Aldrich, E2886) for 1 h at RT, colour was developed with diaminobenzidine (Sigma-Aldrich, D5637). The antibodies were diluted in PBS containing 1% BSA and 10% normal horse serum (Vector, S-2000). Microscopy images were obtained with an Olympus IX70 microscope and a digital camera (CC-12, Soft Imaging System GmbH).
Assessment of neuronal viability (MAP2/ABTS/ELISA)
Neuronal viability was evaluated by MAP2 immunostaining using ABTS (2, 3'-azinobisethylbenzothiazoline-6-sulphonic acid) and absorbance analysis . Neuronal viability was expressed as a percentage of control levels.
Hoechst-33258- and CD11b-positive cells were semi-automatically counted from 20x photomicrographs using ImageJ 1.42I NIH software. For each experiment (n = 4), three wells per condition were used and four fields per well were counted in a blind manner. NOS2-positive cells were counted manually from 20x photomicrographs. For each experiment (n = 11), two wells per condition were used and two fields per well were counted.
Data were analyzed using GraphPad 4.02. Two-way analysis of variance (ANOVA) followed by Bonferroni post-test was used when the effect of genotype on treatment was studied and vice versa. One-way ANOVA was used followed by Dunnet's post-test when comparing versus control or Bonferroni's post-test when comparing versus different experimental conditions. Values of p < 0.05 were considered statistically significant. Error bars are presented in all graphs as standard error of the mean (SEM).
Characterization of C/EBPβ+/+ and C/EBPβ-/- single embryo secondary mixed glial cultures
LPS and LPS+IFNγ upregulate C/EBPβ in secondary mixed glial cultures
Differential C/EBPβ activation is triggered by LPS and LPS+IFNγ
Next, we estimated the binding of C/EBPβ to the promoters of four major pro-inflammatory genes: nitric oxide synthase 2 (NOS2), IL-1β, IL-6 and TNFα, in mixed glial cultures using a qChIP assay (Figure 3B). In untreated glial cultures, no specific binding of C/EBPβ was measurable in any of the four promoters analyzed. However, 2 h after LPS treatment, C/EBPβ binding was observed in the NOS2 promoter. Interestingly, in LPS+IFNγ-treated glial cultures C/EBPβ binding was observed in all four promoters analyzed and, in the case of the NOS2 promoter, C/EBPβ binding was significantly higher than in LPS-treated glial cultures (Figure 3B).
C/EBPβ regulates pro-inflammatory gene expression in glial activation
C/EBPβ-null glial cultures show a marked reduction in NO production
The reduction in LPS+IFNγ-induced NOS2 expression in C/EBPβ-null glial cultures seen by western blot was confirmed by immunocytochemistry. We did not observe by immunocytochemistry any NOS2-positive cells in untreated cultures (not shown), whereas in LPS- (not shown) and LPS+IFNγ-treated wild-type cultures, NOS2 immunoreactivity was observed in 14.0 ± 3.6% of total cells (Figure 5D, E). The vast majority of NOS2-positive cells in LPS+IFNγ-treated wild type mixed glial cultures also expressed CD11b (99.3 ± 1.4%; n = 11) and very rarely NOS2-positive cells expressed GFAP (0.6 ± 1.2%; n = 11) indicating that in these conditions NOS2 expression in mouse cortical mixed glial cultures is predominantly microglial. In C/EBPβ-null cultures the number of NOS2 cells was dramatically reduced after either LPS (not shown) or LPS+IFNγ treatments (Figure 5D, E). As seen in Figure 5D, the reduction of NOS2-positive cells could not be attributed to a reduction in microglial density.
C/EBPβ deficiency in activated microglia abrogates neurotoxicity
The transcription factor C/EBPβ is expressed in glia but no direct evidence exists for its involvement in glial activation. In the present study we show that both LPS and LPS+IFNγ upregulate C/EBPβ expression in mixed glial cultures to a similar extent. Both stimuli also induce C/EBPβ binding to proinflammatory gene promoters but this binding is stronger when induced by LPS+IFNγ. Lack of C/EBPβ results in attenuated expression of proinflammatory genes and, again, this effect is more pronounced when glial cells are activated with LPS+IFNγ than when LPS alone is the activating stimulus. Finally, we describe for the first time that neurotoxicity elicited by LPS+IFNγ-treated microglial cells is completely abrogated by lack of C/EBPβ.
In this study we have used mixed glial cultures composed mainly of astrocytes and microglia. This culture system is our model of choice to study glial activation because it allows cross-talk between the two cell types, which is extremely important in glial activation . Working with astrocytes or microglia in isolation may yield misleading results and there are numerous examples of astroglial or microglial responses that are markedly affected by the absence of the other cell type [37–39]. Regarding C/EBPβ, we have previously shown in experiments with mixed glial and astroglial- or microglial-enriched cultures that, upon activation, C/EBPβ is primarily expressed by microglia with a lesser upregulation in astrocytes . This suggests that the data here reported on C/EBPβ in glial activation mainly reflects C/EBPβ changes in microglia although part of the observed effects could be of astroglial origin. However, in the case of the effects of C/EBPβ absence on NOS2 expression and neurotoxicity, the observed effects are clearly microglial, as shown by the microglial localization of NOS2 immunoreactivity and by the use of isolated microglia, respectively.
Most protocols to prepare primary mixed glial cultures from rodents use pools of tissue from several neonates, generally one or two litters. Since C/EBPβ females are sterile  litters of C/EBPβ-null neonates cannot be obtained. Furthermore, approximately 50% of C/EBPβ-null pups die perinatally  which favors the use of late embryos instead of neonates to ensure a maximum number of available C/EBPβ-null mice. Therefore, we established for this study a new protocol of secondary mixed glial cultures by subculturing primary glial cultures prepared from the cerebral cortex of a single E19-E20 embryo. The use of secondary cultures was particularly suitable for this project because we could prepare mixed glial cultures that were very similar to primary cultures in terms of cell density and proportions with a more-than-2-fold higher yield. Besides, the use of siblings eliminates any genetic background effect. Altogether, this makes the use of secondary mixed glial cultures from a single embryo or neonate a useful approach when working with mouse strains of compromised fertility.
LPS is a toll-like receptor 4 agonist that induces marked changes in gene expression in astrocytes and microglia . The combination of LPS, a pathogen factor, with IFNγ, a host factor, potentiates some of the LPS-induced effects . Here we report for the first time a proper comparison between LPS and LPS+IFNγ effects on C/EBPβ and on pro-inflammatory markers in glial cells. We have observed that both LPS and LPS+IFNγ induce similar increases in C/EBPβ mRNA and protein levels as well as in DNA binding. Time-course analyses have revealed that upregulation of the C/EBPβ activating isoforms Full/LAP often precedes upregulation of the inhibitory isoform LIP [21, 24, 42]. When a single time-point is analyzed, as in the present study, the simultaneous increase in activating and inhibitory C/EBPβ isoforms is a common observation. EMSA analysis with supershift experiments showed the presence of C/EBPβ in bands I, II and III. These bands may contain different C/EBPβ isoforms (Full, LAP or LIP) with various post-translational modifications (phosphorylation, SUMOylation or acetylation has been described ). It is likely that some of these bands contain more than one complex (e.g. band II since it is only partially supershifted by anti-C/EBPβ) and that some of these complexes contain other transcription factors, p65-NFκB  and C/EBPδ [45, 46] being two of the most likely candidates to form complexes with C/EBPβ in neuroinflammation. An extensive biochemical analysis would be necessary to characterize the transcriptional C/EBPβ complexes in activated glial cells.
This study shows for the first time in glial cells an analysis of mRNA levels for the pro-inflammatory genes NOS2, IL-1β, IL-6 and TNFα, comparing LPS and LPS+IFNγ as activating stimuli. In this model, IFNγ alone did not trigger any effect (data not shown) whereas LPS and LPS+IFNγ upregulated all four pro-inflammatory genes analyzed. LPS and LPS+IFNγ increased expression of IL-1β, IL-6 and TNFα to the same extent, as reported for macrophages , whereas LPS-induced upregulation of NOS2 was markedly potentiated by cotreatment with IFNγ, in agreement with previous observations in microglia  and macrophages . Even though transcriptional levels of cytokine genes in LPS-treated glial cultures are not modulated by cotreatment with IFNγ, their promoter regions undergo a remodeling of transcriptional complex as proved by qChIP assay. mRNA analysis showed that absence of C/EBPβ does not affect LPS-induced upregulation of the three cytokines, in agreement with absence of C/EBPβ binding to IL-1β, IL-6 or TNFα promoters in LPS-treated glial cultures, as seen by qChIP. Although we cannot exclude the presence of C/EBPβ in other promoter regions, because we focused our promoter analysis on the C/EBPβ consensus sequence most proximal to the translation start site, these data strongly suggest that C/EBPβ does not participate in the LPS-induced expression of these three genes in the present model. It may seem contradictory that strong C/EBPβ binding to IL-1β, IL-6 and TNFα promoters was induced by LPS+IFNγ, but not by LPS alone, whereas the levels of these cytokine mRNAs were similar after treatment with either LPS or LPS+IFNγ. In our opinion, this indicates that different sets of transcription factors act on these promoters after LPS or LPS+IFNγ treatment or, in other words, that there is IFNγ-induced chromatin remodeling on these promoters . This is also suggested by the qPCR data showing that LPS+IFNγ-induced expression of IL-1β is reduced in the absence of C/EBPβ, and that there is also a tendency toward reduced expression of TNFα and IL-6. These data demonstrate for the first time that C/EBPβ plays a role in transactivation of pro-inflammatory cytokine genes in glial cells induced by LPS+IFNγ but not by LPS alone.
In our glial activation model, the NOS2 gene shows a different transcription pattern when compared with the pro-inflammatory cytokines. On the one hand, as mentioned before, LPS-induced NOS2 expression is potentiated by co-treatment with IFNγ. On the other hand, C/EBPβ binding to the NOS2 promoter is already seen after LPS treatment alone and, interestingly, this binding is potentiated by IFNγ treatment. As observed in macrophage cell lines, IFNγ can trigger C/EBPβ phosphorylation, modulating its capacity to form transcriptional complexes with p300  or Med1 . Also, IFNγ can promote C/EBPβ DNA binding activity to IFN-stimulated regulatory elements (ISREs) which we have found tightly associated with C/EBPβ consensus sequences on the mouse NOS2 promoter (unpublished observations). Finally, both LPS- and LPS+IFNγ-induced increases in NOS2 expression are attenuated in the absence of C/EBPβ. These findings suggest that C/EBPβ plays a functional role both in LPS-induced NOS2 expression and in the potentiation of this effect elicited by IFNγ. In accordance with the multiple stage glial activation model , we can hypothesize that LPS alone activates the glia, but that only with a host warning signal, such as IFNγ, are glia totally committed to a hyper-reactive phenotype. We propose that C/EBPβ could trigger this shift through the executive phase of glial activation.
The hypothesis of a pathogenic role for exacerbated glial activation, particularly activation of microglia, is based on the known in vitro neurotoxic effects of activated microglia [53, 54], on the protective effects of anti-inflammatory treatments or genetic modifications in animal models of neurodegenerative disorders [55, 56] and on epidemiological data [57–59]. Since we have shown in this study that C/EBPβ deficiency attenuates expression of potentially neurotoxic pro-inflammatory mediators but not that of anti-inflammatory cytokines, we were interested to test the hypothesis that C/EBPβ plays a key role in the induction of detrimental effects by microglial activation. Reduced neuronal damage after ischemic  or excitotoxic insults  has been observed in C/EBPβ-null mice. Even though C/EBPβ expression has been reported in activated glial cells [22–24], C/EBPβ is known to be also expressed in the adult mouse by neurons  and peripheral cells . Consequently, the neuroprotective effect observed in C/EBPβ-null mice could be mediated by lack of C/EBPβ in any of these cells. We show here that the neurotoxicity elicited by activated wild-type microglial cells co-cultured with wild-type neurons is completely abolished by the absence of C/EBPβ specifically in microglia. This strongly supports a role of C/EBPβ in the regulation of potentially neurotoxic effects of microglia and suggests that the neuroprotective effects of total C/EBPβ absence in vivo [26, 27] are due to microglial C/EBPβ deficiency. Specific microglial C/EBPβ deletion would be very informative to clarify the role of microglial C/EBPβ in neurodegeneration in in vivo models of neurological disease.
In summary, this study shows that LPS and LPS+IFNγ induce expression of C/EBPβ in mixed glial cultures, and both stimuli also induce differential binding of C/EBPβ to proinflammatory gene promoters. A functional role for C/EBPβ in glial activation is demonstrated by the attenuated gene expression and abrogation of neurotoxicity in microglial cells devoid of C/EBPβ. Altogether, these findings point to C/EBPβ as a key transcription factor in the molecular reprogramming that occurs in microglial activation and suggest that C/EBPβ is a possible therapeutic target to ameliorate neuronal damage of neuroinflammatory origin.
List of abbreviations
2, 3'-azinobisethylbenzothiazoline-6-sulphonic acid
Analysis of variance
CCAAT/enhancer binding protein β
Days in vitro
Glial fibrillary acidic protein
Quantitative chromatin immunoprecipitation
Quantitative real time PCR
Transforming growth factor β1
Tumour necrosis factor-α
We thank Colleen Croniger and Valeria Poli for the generous gift of C/EBPβ knockout mice, Teresa Domingo and colleagues at animal facilities of the School of Pharmacy (University of Barcelona) for the professional care of C/EBPβ knockout mice and Tony Valente for technical assistance. Marco Straccia and Nuria Gresa-Arribas are recipients of JAE contracts from CSIC. Guido Dentesano is a recipient of IDIBAPS fellowship contract. This study was supported by grants PI07/455, PI08/1396 and P10/378 from the Instituto de Salud Carlos III, Spain.
- Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P: Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol. 2009, 210: 3-12. 10.1016/j.jneuroim.2009.02.003.View ArticlePubMed
- Cho IH, Hong J, Suh EC, Kim JH, Lee H, Lee JE, Lee S, Kim CH, Kim DW, Jo EK, Lee KE, Karin M, Lee SJ: Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008, 131: 3019-3033. 10.1093/brain/awn230.PubMed CentralView ArticlePubMed
- Kaltschmidt B, Widera D, Kaltschmidt C: Signaling via NF-kappaB in the nervous system. Biochim Biophys Acta. 2005, 1745: 287-299. 10.1016/j.bbamcr.2005.05.009.View ArticlePubMed
- Kwon D, Fuller AC, Palma JP, Choi IH, Kim BS: Induction of chemokines in human astrocytes by picornavirus infection requires activation of both AP-1 and NF-kappa B. Glia. 2004, 45: 287-296. 10.1002/glia.10331.View ArticlePubMed
- Kim OS, Park EJ, Joe EH, Jou I: JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells. J Biol Chem. 2002, 277: 40594-40601. 10.1074/jbc.M203885200.View ArticlePubMed
- Wang X, Li C, Chen Y, Hao Y, Zhou W, Chen C, Yu Z: Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem Biophys Res Commun. 2008, 371: 283-288. 10.1016/j.bbrc.2008.04.055.View ArticlePubMed
- Zhang W, Petrovic JM, Callaghan D, Jones A, Cui H, Howlett C, Stanimirovic D: Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J Neuroimmunol. 2006, 174: 63-73. 10.1016/j.jneuroim.2006.01.014.View ArticlePubMed
- Friedle SA, Brautigam VM, Nikodemova M, Wright ML, Watters JJ: The P2X7-Egr pathway regulates nucleotide-dependent inflammatory gene expression in microglia. Glia. 2011, 59: 1-13. 10.1002/glia.21071.PubMed CentralView ArticlePubMed
- Iadecola C, Salkowski CA, Zhang F, Aber T, Nagayama M, Vogel SN, Ross ME: The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med. 1999, 189: 719-727. 10.1084/jem.189.4.719.PubMed CentralView ArticlePubMed
- Drew PD, Xu J, Storer PD, Chavis JA, Racke MK: Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int. 2006, 49: 183-189. 10.1016/j.neuint.2006.04.003.View ArticlePubMed
- Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA: Nrf2, a multi-organ protector?. FASEB J. 2005, 19: 1061-1066. 10.1096/fj.04-2591hyp.View ArticlePubMed
- Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH: Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci. 2003, 23: 3394-3406.PubMed
- Ossipow V, Descombes P, Schibler U: CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci USA. 1993, 90: 8219-8223. 10.1073/pnas.90.17.8219.PubMed CentralView ArticlePubMed
- Welm AL, Timchenko NA, Darlington GJ: C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage. Mol Cell Biol. 1999, 19: 1695-1704.PubMed CentralView ArticlePubMed
- Greenbaum LE, Li W, Cressman DE, Peng Y, Ciliberto G, Poli V, Taub R: CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. J Clin Invest. 1998, 102: 996-1007. 10.1172/JCI3135.PubMed CentralView ArticlePubMed
- Ramji DP, Foka P: CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002, 365: 561-575.PubMed CentralView ArticlePubMed
- Poli V: The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem. 1998, 273: 29279-29282. 10.1074/jbc.273.45.29279.View ArticlePubMed
- Caivano M, Gorgoni B, Cohen P, Poli V: The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta) and C/EBP delta transcription factors. J Biol Chem. 2001, 276: 48693-48701. 10.1074/jbc.M108282200.View ArticlePubMed
- Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, Murphy WJ: Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci USA. 1993, 90: 9730-9734. 10.1073/pnas.90.20.9730.PubMed CentralView ArticlePubMed
- Reddy ST, Wadleigh DJ, Herschman HR: Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J Biol Chem. 2000, 275: 3107-3113. 10.1074/jbc.275.5.3107.View ArticlePubMed
- Bradley MN, Zhou L, Smale ST: C/EBPbeta regulation in lipopolysaccharide-stimulated macrophages. Mol Cell Biol. 2003, 23: 4841-4858. 10.1128/MCB.23.14.4841-4858.2003.PubMed CentralView ArticlePubMed
- Cardinaux JR, Allaman I, Magistretti PJ: Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia. 2000, 29: 91-97. 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I.View ArticlePubMed
- Cardinaux JR, Magistretti PJ: Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism. J Neurosci. 1996, 16: 919-929.PubMed
- Ejarque-Ortiz A, Medina MG, Tusell JM, Perez-Gonzalez AP, Serratosa J, Saura J: Upregulation of CCAAT/enhancer binding protein beta in activated astrocytes and microglia. Glia. 2007, 55: 178-188. 10.1002/glia.20446.View ArticlePubMed
- Perez-Capote K, Saura J, Serratosa J, Sola C: Expression of C/EBPalpha and C/EBPbeta in glial cells in vitro after inducing glial activation by different stimuli. Neurosci Lett. 2006, 410: 25-30. 10.1016/j.neulet.2006.09.078.View ArticlePubMed
- Kapadia R, Tureyen K, Bowen KK, Kalluri H, Johnson PF, Vemuganti R: Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia. J Neurochem. 2006, 98: 1718-1731. 10.1111/j.1471-4159.2006.04056.x.View ArticlePubMed
- Cortes-Canteli M, Luna-Medina R, Sanz-Sancristobal M, Alvarez-Barrientos A, Santos A, Perez-Castillo A: CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury. J Cell Sci. 2008, 121: 1224-1234. 10.1242/jcs.025031.View ArticlePubMed
- Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D, Sellitto C, Scarpa S, Bellavia D, Lattanzio G, Bistoni F, Frati L, Cortese R, Gulino A, Ciliberto G, Constantini F, Poli V: Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995, 14: 1932-1941.PubMed CentralPubMed
- Giulian D, Baker TJ: Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci. 1986, 6: 2163-2178.PubMed
- Saura J, Tusell JM, Serratosa J: High-yield isolation of murine microglia by mild trypsinization. Glia. 2003, 44: 183-189. 10.1002/glia.10274.View ArticlePubMed
- Gresa-Arribas N, Serratosa J, Saura J, Sola C: Inhibition of CCAAT/enhancer binding protein delta expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects. J Neurochem. 2010, 115: 526-536. 10.1111/j.1471-4159.2010.06952.x.View ArticlePubMed
- Saura J, Petegnief V, Wu X, Liang Y, Paul SM: Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J Neurochem. 2003, 85: 1455-1467. 10.1046/j.1471-4159.2003.01788.x.View ArticlePubMed
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMed
- Buira SP, Dentesano G, Albasanz JL, Moreno J, Martin M, Ferrer I, Barrachina M: DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain. J Neurochem. 2010, 115: 283-295. 10.1111/j.1471-4159.2010.06928.x.View ArticlePubMed
- Liu YW, Tseng HP, Chen LC, Chen BK, Chang WC: Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. J Immunol. 2003, 171: 821-828.View ArticlePubMed
- Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH: Mechanisms underlying inflammation in neurodegeneration. Cell. 2010, 140: 918-934. 10.1016/j.cell.2010.02.016.PubMed CentralView ArticlePubMed
- Sola C, Casal C, Tusell JM, Serratosa J: Astrocytes enhance lipopolysaccharide-induced nitric oxide production by microglial cells. Eur J Neurosci. 2002, 16: 1275-1283. 10.1046/j.1460-9568.2002.02199.x.View ArticlePubMed
- Saura J, Angulo E, Ejarque A, Casado V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J: Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem. 2005, 95: 919-929. 10.1111/j.1471-4159.2005.03395.x.View ArticlePubMed
- Saura J: Microglial cells in astroglial cultures: a cautionary note. J Neuroinflammation. 2007, 4: 26-10.1186/1742-2094-4-26.PubMed CentralView ArticlePubMed
- Sterneck E, Tessarollo L, Johnson PF: An essential role for C/EBPbeta in female reproduction. Genes Dev. 1997, 11: 2153-2162. 10.1101/gad.11.17.2153.PubMed CentralView ArticlePubMed
- Schroder K, Sweet MJ, Hume DA: Signal integration between IFNgamma and TLR signalling pathways in macrophages. Immunobiology. 2006, 211: 511-524. 10.1016/j.imbio.2006.05.007.View ArticlePubMed
- Meir O, Dvash E, Werman A, Rubinstein M: C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models. PLoS One. 2010, 5: e9516-10.1371/journal.pone.0009516.PubMed CentralView ArticlePubMed
- Nerlov C: C/EBPs: recipients of extracellular signals through proteome modulation. Curr Opin Cell Biol. 2008, 20: 180-185. 10.1016/j.ceb.2008.02.002.View ArticlePubMed
- Xia C, Cheshire JK, Patel H, Woo P: Cross-talk between transcription factors NF-kappa B and C/EBP in the transcriptional regulation of genes. Int J Biochem Cell Biol. 1997, 29: 1525-1539. 10.1016/S1357-2725(97)00083-6.View ArticlePubMed
- Ejarque-Ortiz A, Gresa-Arribas N, Straccia M, Mancera P, Sola C, Tusell JM, Serratosa J, Saura J: CCAAT/enhancer binding protein delta in microglial activation. J Neurosci Res. 2010, 88: 1113-1123.View ArticlePubMed
- Ramberg V, Tracy LM, Samuelsson M, Nilsson LN, Iverfeldt K: The CCAAT/enhancer binding protein (C/EBP) delta is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-beta peptide. J Neuroinflammation. 2011, 8: 34-10.1186/1742-2094-8-34.PubMed CentralView ArticlePubMed
- Gorgoni B, Maritano D, Marthyn P, Righi M, Poli V: C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. J Immunol. 2002, 168: 4055-4062.View ArticlePubMed
- Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE: Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol. 1993, 151: 2132-2141.PubMed
- Chen J, Ivashkiv LB: IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc Natl Acad Sci USA. 2010, 107: 19438-19443. 10.1073/pnas.1007816107.PubMed CentralView ArticlePubMed
- Schwartz C, Beck K, Mink S, Schmolke M, Budde B, Wenning D, Klempnauer KH: Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity. EMBO J. 2003, 22: 882-892. 10.1093/emboj/cdg076.PubMed CentralView ArticlePubMed
- Li H, Gade P, Nallar SC, Raha A, Roy SK, Karra S, Reddy JK, Reddy SP, Kalvakolanu DV: The Med1 subunit of transcriptional mediator plays a central role in regulating CCAAT/enhancer-binding protein-beta-driven transcription in response to interferon-gamma. J Biol Chem. 2008, 283: 13077-13086. 10.1074/jbc.M800604200.PubMed CentralView ArticlePubMed
- Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007, 10: 1387-1394. 10.1038/nn1997.View ArticlePubMed
- Katsuki H, Okawara M, Shibata H, Kume T, Akaike A: Nitric oxide-producing microglia mediate thrombin-induced degeneration of dopaminergic neurons in rat midbrain slice culture. J Neurochem. 2006, 97: 1232-1242. 10.1111/j.1471-4159.2006.03752.x.View ArticlePubMed
- Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, Longo VD: Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J Neurosci. 2002, 22: 3484-3492.PubMed
- Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med. 1999, 5: 1403-1409. 10.1038/70978.View ArticlePubMed
- Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS: Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci. 2007, 27: 3328-3337. 10.1523/JNEUROSCI.5321-06.2007.View ArticlePubMed
- Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005, 58: 963-967. 10.1002/ana.20682.View ArticlePubMed
- Gao X, Chen H, Schwarzschild MA, Ascherio A: Use of ibuprofen and risk of Parkinson disease. Neurology. 2011, 76: 863-869. 10.1212/WNL.0b013e31820f2d79.PubMed CentralView ArticlePubMed
- in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM: Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001, 22: 407-412. 10.1016/S0197-4580(00)00241-4.View ArticlePubMed
- Sterneck E, Johnson PF: CCAAT/enhancer binding protein beta is a neuronal transcriptional regulator activated by nerve growth factor receptor signaling. J Neurochem. 1998, 70: 2424-2433.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.